Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| American Lung Association | OTHER |
Not provided
Not provided
Not provided
Not provided
The aim of this study is to evaluate the efficacy of a brief psychoeducational intervention to improve quality of life in patients with lung cancer who are transitioning from active treatment to surveillance.
This is a randomized controlled trial to test the efficacy of a brief psychoeducational intervention relative to a control condition for improving quality of life in patients with lung cancer who are transitioning from treatment to surveillance.
In this study, participants will complete survey questions and will be randomly assigned to receive a 5-session program or a 1-session program.
It is expected that about 100 people will take part in this research study.
The American Lung Association is supporting this research by providing funding for the research study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention: Five Psycho-educational Sessions | Experimental | Approximately 6 weeks after the patient's cancer treatment is complete, participants in the intervention arm will proceed to receive up to 5 study sessions (approximately weekly, ~50 minutes each) with a trained interventionist focused on psychoeducational topics. This arm was designed to enhance patient skills to address key concerns during the transition from treatment to surveillance, using a cognitive-behavioral approach. Sessions will be based on an intervention manual. |
|
| Enhanced Usual Care: One Psycho-educational Session | Experimental | At approximately 6 weeks after treatment completion (as defined by our eligibility criteria), control patients will attend one study session (~50 minutes) with a study clinician. This session is designed to control for patient access and connection to psychosocial resources as recommended in recent work. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Five Psycho-educational Session(s) | Behavioral | 5 psychoeducational sessions focused on skills for enhancing wellbeing, relationships, social support, and ability to cope with uncertainty |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of life: Functional Assessment of Cancer Therapy-Lung Cancer | We will investigate longitudinal differences in quality of life between study groups (Functional Assessment of Cancer Therapy-Lung Cancer score range 0-144, with higher scores indicating better quality of life) | Up to 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Fear of cancer recurrence: Fear of Cancer Recurrence Scale 7 | We will investigate longitudinal differences in fear of cancer recurrence between study groups (Fear of Cancer Recurrence Scale 7, score range 7-35, with higher scores indicating more fear of cancer recurrence) | Up to 12 weeks |
| Symptom burden: Edmonton Symptom Assessment Scale |
Not provided
Inclusion Criteria:
Age 21 or older
Able to read and respond in English
Diagnosis of non-small cell lung cancer or small cell lung cancer
Documented curative treatment plan including systemic therapy +/- radiation and +/- surgery
Completed cancer treatment within past 3 weeks
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lara Traeger, PhD | Massachusetts General Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Massachusetts General Hospital Cancer Center | Boston | Massachusetts | 02114 | United States | ||
| Dana-Farber Cancer Institute |
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Data can be shared no earlier than 1 year following the date of publication
Contact the Partners Innovations team at http://www.partners.org/innovation
Not provided
Not provided
| ID | Term |
|---|---|
| D008175 | Lung Neoplasms |
| ID | Term |
|---|---|
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| One Psycho-educational Session(s) | Behavioral | 1 session focused on exploring goals and expectations for post-treatment quality of life, including supportive listening; assessment of unmet needs; preferences for support, and tailored referral recommendations |
|
We will investigate longitudinal differences in symptom burden (Edmonton Symptom Assessment Scale score range 0-90, with higher scores indicating more symptom burden) |
| Up to 12 weeks |
| Psychological symptom burden: Hospital Anxiety and Depression Scale | We will investigate longitudinal differences in psychological symptom burden (Hospital Anxiety and Depression Scale score range 0-42 with higher scores indicating more psychological symptom burden) | Up to 12 weeks |
| Social support: Multidimensional Scale of Perceived Social Support | We will investigate longitudinal differencs in social support (Multidimensional Scale of Perceived Social Support score range 12-84, with higher scores indicating more social support) | Up to 12 weeks |
| Social isolaton: Campaign to End Loneliness Measurement Tool | We will investigate longitudinal differences in social isolation (Campaign to End Loneliness measurement tool score range 0-12 with higher scores indicating more social isolation) | Up to 12 weeks |
| Boston |
| Massachusetts |
| 02215 |
| United States |
| D008171 |
| Lung Diseases |
| D012140 | Respiratory Tract Diseases |